Atrial Fibrillation at Risk for Stroke
Atrial fibrillation (AF) is the most common type of arrhythmia (irregular heart beat). It has been estimated that about 33.5 million patients worldwide are affected by AF. People with atrial fibrillation may not have any symptom but are at higher risk of stroke. Currently, atrial fibrillation-related stroke risk can be reduced by taking anticoagulant drugs. However, these drugs may increase the risk of bleeding.
What is the purpose of the study?
The purpose of the OCEANIC-AF clinical study is to learn if the investigational drug asundexian:
- Is effective when compared to apixaban (how well it works in participants with atrial fibrillation)
- Is safe when compared to apixaban (can it decrease the risk of bleeding)
- How it affects the body
The comparator, apixaban, is a standard approved anticoagulant drug for stroke prevention in atrial fibrillation. It is not known whether participants will get any benefit from participating in this study. As with any drug, side effects may happen when taking the investigational drug
You may qualify if:
- You have a history of atrial fibrillation within the past 12 months
- You are taking an oral anticoagulant for your atrial fibrillation
View study on ClinicalTrials.gov